Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
about
A phase I and pharmacokinetic study of intraperitoneal topotecanSustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.Gynaecological cancer.Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancerEGFR Targeted Theranostic Nanoemulsion for Image-Guided Ovarian Cancer Therapy.Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials.Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.Intraperitoneal photodynamic therapy of the rat CC531 adenocarcinoma.Reduced expression of BAX is associated with poor prognosis in patients with epithelial ovarian cancer: a multifactorial analysis of TP53, p21, BAX and BCL-2A dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer.Targeting signaling pathways in epithelial ovarian cancer.Recent Advancements in Prognostic Factors of Epithelial Ovarian Carcinoma.Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerValue of quantitative pathological variables as prognostic factors in advanced ovarian carcinoma.Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancerOxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer.Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.Does Aquaporin-1 expression have clinical significance in serous epithelial ovarian cancer?Optimal chemotherapy of ovarian cancer with an old regimen.High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer.Activity of anthracyclines in refractory ovarian cancer: recent experience and review.Pegylated liposomal doxorubicin for platinum-resistant or refractory Müllerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): A single-institutional experience.Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results.Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP.Survival of Advanced Stage High-Grade Serous Ovarian Cancer Patients in the Republic of Macedonia.
P2860
Q28366214-41E4ACC4-276F-4EC9-896E-ED86BECD7F8EQ33396185-9604DF26-E507-40C9-A3DC-DC4FA8263F4BQ33704172-06262467-2BDB-4FC8-8F62-1D55D65B85E5Q34214594-FE2DE351-5B17-4CFA-A6F2-8A4106D3E55AQ35812462-F2151D40-C210-4E46-A826-A46BFA15E89FQ35978030-C1468F62-A789-45CF-86B3-CDAF60C15914Q36081774-8A2D12C4-222E-4CA3-9D99-F5748243B0C0Q36116134-47D4A2C8-B931-4CD5-9EC4-56344270B9E4Q36135116-C35A0BCD-ED5B-4D62-BFC3-9426745CC833Q36643987-CC6225FA-A1E6-48AD-B4FA-D62C51C26375Q36644381-0020A82D-7466-4E00-872D-98A46630220DQ36913614-AF51507F-DCBE-41CB-92DA-04E0358C614CQ36979335-C0631CAF-2D5C-4A05-A3D2-D908BD7BFC7AQ37123465-CC97A861-A27E-4580-9D3A-D1074886F9C8Q37214269-AA725116-D7D2-4D1B-B55D-313AC0A85880Q37248561-B239EC50-8239-4600-A11C-173BE9054CB9Q37296274-6CAD51D4-3673-4961-96A7-581854528481Q37352629-FA4A5463-6798-40B4-88DA-5F5DEC7ADB9CQ37474070-70B1A9E6-81D5-4E6E-BAC5-1DB1339B54C8Q37591828-F835199B-0CFF-44CD-AB38-CD6FCB124706Q40520307-8781B696-D0C9-45DD-A7EE-625C1502C68BQ41056700-8534195D-E339-4A4F-B433-C3D53C74755DQ41552408-A53B0C01-3E7D-4D05-94A5-3F73E8C87799Q42416643-865CBD0A-D2F9-4384-B5F1-B1F582AC3921Q43203991-1D21A35D-D6AB-4287-9437-E15F850C3AD9Q43662943-76867399-17A1-492E-B761-659731099228Q44128397-F2F25C14-0D1C-47DE-B858-F3CF7F0B2178Q49518656-D234BCBF-F91C-4D29-BF0A-1BBE5A7A26DE
P2860
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
description
1991 nî lūn-bûn
@nan
1991 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@ast
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@en
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@nl
type
label
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@ast
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@en
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@nl
prefLabel
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@ast
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@en
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@nl
P2093
P1476
Long-term survival in ovarian ...... tudy Group for Ovarian Cancer.
@en
P2093
Vermorken JB
Willemse PH
ten Bokkel Huinink WW
van Lent M
van Lindert AC
van Oosterom AT
van der Burg ME
P304
P356
10.1016/0277-5379(91)90011-2
P577
1991-01-01T00:00:00Z